© 2024 © 2020 Genprex Inc. All Rights Reserved.
Cancer is a complex disease that can be difficult treat. Lung cancer specifically is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, kidney, liver or prostate cancers.
Genprex recently announced that independent researchers found that company’s TUSC2 (tumor suppressor candidate 2) prevented tumor growth in triple-negative breast cancer (TNBC). These independent researchers have no affiliation with Genprex.
AUSTIN, Texas & CAMBRIDGE, Mass.— (September 18, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will present at the Singular Research Midwestern Values Conference on September 19, 2019 via webcast.
Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, is raising the standard in cancer treatment by developing what it calls an “immunogene therapy,” which harnesses the power of immunotherapy’s immunomodulation through the delivery of a gene therapy.
A direct target of miR-138, TUSC2 mimics miR-138 knockdown
AUSTIN, Texas & CAMBRIDGE, Mass.— (September 11, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options….
AUSTIN, Texas & CAMBRIDGE, Mass.— (September 5, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will present at the H.C. Wainwright 21stAnnual Global Investment Conference on September 9, 2019 in New York City.
AUSTIN, Texas & CAMBRIDGE, Mass.— (September 3, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex™ immunogene therapy, to market.